Vasculitis & polymyalgia rheumatica
Patient‐Reported Sinonasal Symptoms and Risk of Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Main finding · Risk of relapse with higher SNOT-22 scores (all AAV)Result — go to the resultHazard ratio 2.7 95% CI 1.2–6.2Authors' conclusion
A patient-reported outcome measure of sinonasal disease, the SNOT-22, not only changes with disease activity in AAV, but also is associated with a higher risk of relapse within two years.
Study context
- Population
- Individuals with antibody-associated vasculitis (AAV) and healthy individuals773 visits (106 active disease)
- Participants
- 168 vs 51
- Exposure
- Patients with AAV vs healthy controls; SinoNasal Outcome Test (SNOT-22) scores and risk of relapse
- AAVn = 168
- Controlsn = 51reference
- Outcome
- Association between SNOT-22 and relapse (BVAS for Wegener's Granulomatosis score >0)
Methodological detailslongitudinal, generalized estimating equation and Cox proportional hazard models
- Longitudinal
- Generalized estimating equation and Cox proportional hazard models
Main finding
As reported in the abstract
Risk of relapse with higher SNOT-22 scores (all AAV)
Hazard ratio
2.7
95% CI 1.2–6.2
P = 0.02
Higher SNOT-22
HR 2.7 (95% CI 1.2–6.2); P = 0.02
Observational data: associations, not effects.
Further findings
Median
| Outcome | AAV | Controls | P value |
|---|---|---|---|
| Median SNOT-22 at remission | 20 | 5 | P < 0.001 |
SNOT-22 during active disease vs remission
- Higher during active disease vs remission
- P < 0.001
Patients with vs without sinonasal disease; after removing ENT-limited relapses
- Similar findings
Original publication
Patient‐Reported Sinonasal Symptoms and Risk of Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis Care Res (Hoboken). Published 15 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →